ACT GENOMICS CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
SOLUTION -
1. Genomic Tests
2. For Professionals
3. For Patients
4. For Biopharma
1. Genomic Tests
2. For Professionals
3. For Patients
4. For Biopharma
The content above was translated by Ai
Founded Year
2013
Unified Business No.
54650959
Status
Active
Number of Employees
0
Total Paid-in
Capital
455,080,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Acquired(2025)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
ACT Genomics is an award-winning cancer solution provider founded in 2014 by a small group of scientists from academia. With our name, ACT Genomics, reflecting our passion to “turn genomics into action”, we set out to apply academic theories in clinical practice and truly make personalized cancer care accessible to all.
Over the years, our practical experience has helped academic research make remarkable progress, which has in turn enhanced our cancer solutions with high efficiency and accuracy. As a pioneer in Taiwan and the wider Asian region, we are committed to empowering cancer patients with advanced genomic treatments and continuing to make strides forward in precision medicine.
Over the years, our practical experience has helped academic research make remarkable progress, which has in turn enhanced our cancer solutions with high efficiency and accuracy. As a pioneer in Taiwan and the wider Asian region, we are committed to empowering cancer patients with advanced genomic treatments and continuing to make strides forward in precision medicine.
The content above was translated by Ai
